Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan sued over plans for Vytorin generic, and claims first-filer status

This article was originally published in Scrip

Executive Summary

Mylan has initiated a challenge to key US patents covering the hypolipaemic, Merck & Co's Vytorin (ezetimibe plus simvastatin), seeking to market a generic of the product before expiry of US patents. Following the submission of its ANDA with a paragraph IV challenge, the company said it was sued by Schering and MSP Singapore Company in the US District Court for the District of New Jersey. The suit triggers the 30-month stay of approval while the legal challenge is fought.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts